• FDA Grants Nucynta New Indication

    by  • 10 November 2011 • Pain News

    This is the second indication given to the oral μ-opioid agonist. Nucynta, a centrally acting synthetic agent, was previously approved for the treatment of acute pain. The ER formulation is taken twice daily when 24-hour pain relief is needed for extended periods.


    After thirty years in the investment and public relations field, we have switched our focus lobbing between American and European companies facilitating business and licensing opportunities . Starting in the year 2003 L.G.Zangani, LLC has organized the annual event "Pharmafinance" in Milano and Roma. Pharmafinance is unique in its structure and has the ability to expose opportunities generated offering licensing or developing opportunities. Recently we have started the site www.letcombatpain.com creating the first worldwide site for pain news. The site also offers an humanitarian tools where individuals or professionals confronted by unique and rare forms of pain can communicate with all the members of the group simply sending oneemail. This ability of having a mass communication tool can also be used to expose innovative pain products or ideas. Additionally has also been invited as speaker to several conferences in Europe to discuss the uniqueness and functionality of his site .